– USA, MA – AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Dr. Derek Adams (Ph.D.) to its Board of Directors, effective March 1st, 2023, bringing more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
“I am thrilled that Derek is joining AlloVir’s Board of Directors at this important time as the Company looks toward the completion of our posoleucel Phase 3 studies, and potential regulatory submissions and commercial launches. His experience successfully advancing the manufacturing of complex biologic and gene therapies from clinical development to commercialization will be a tremendous asset as we drive posoleucel through Phase 3 and beyond,” said CEO, Dr. Diana Brainard.
The company also announced that Dr. Ansbert Gadicke will step down from the Board at the end of February.
About Dr. Derek Adams
Dr. Adams has extensive experience in building manufacturing capabilities and navigating the regulatory Chemistry, Manufacturing, and Controls landscape from development through commercialization for advanced medicinal products including cell therapies. He currently serves as CEO of Stellular Bio, a private biotechnology company pioneering a platelet-inspired cell therapy platform for regenerative medicine, and previously served as President and CEO of PlateletBio. Before these roles, Dr. Adams spent more than two decades leading CMC for clinical- and commercial-stage biologics and gene therapy companies. He served as Chief Technology and Manufacturing Officer at bluebird bio, SVP of CMC at Evelo Biosciences, and VP of Technical and Strategic Product Development at Alexion Pharmaceuticals.
Dr. Adams received his Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. with High Distinction from Worcester Polytechnic Institute.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for treating and preventing a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid and late-stage clinical trials across its product portfolio.
For more information: https://www.allovir.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
